• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Merial launches first firocoxib for horses

July 1, 2007

DULUTH,GA.-EQUIOXX® (firocoxib) is a new nonsteroidal anti-inflammatory drug (NSAID) from Merial to relieve pain and inflammation associated with osteoarthritis (OA) in horses.

DULUTH,GA.—EQUIOXX® (firocoxib) is a new nonsteroidal anti-inflammatory drug (NSAID) from Merial to relieve pain and inflammation associated with osteoarthritis (OA) in horses.

Approved by the Food and Drug Administration (FDA),EQUIOXX is a coxibclass NSAID, and the first new NSAID entity in many years to be registered for oral use in horses. In trials, EQUIOXX paste was shown to improve the mobility of treated horses,Merial reports.

"Field trials with EQUIOXX have provided impressive results in reducing pain and inflammation associated with osteoarthritis in horses" says Peter Hanson, DVM,PhD,Dipl.ACVS, executive director, pharmaceutical R&D projects for Merial."EQUIOXX provides veterinarians a long-awaited new NSAID that has an excellent safety profile."

Advertisement

To evaluate the efficacy of EQUIOXX, horses were rated for improvement in a study based on four variables: lameness, pain on manipulation, joint swelling and range ofmotion;results showed 84 percent ofhorses treated with EQUIOXX improved.

A targeted study evaluated clinically relevant side effects related to long-term treatment at one to five times a dose. In the study, 30 horses of various breeds and sizes received doses of 0.1 to 0.5 mg firocoxib/kg/day for 30 days. Results showed no treatment-related side effects for body weight change, bleeding time, urinalysis parameters,gastric ulcer scores and renal toxicity. Clinical pathology and gross and histopathologic lesions were also measured at various dosing levels.At a 1X (actual dose) and even at a 3X dose,groups did not experience any clinical pathology side effects. The 5X dose group had lowered red blood-cell count, hematocrit, hemoglobin, total protein,albumin and globulin that were likely associated with parasitism. No cases of gross or histopathologic lesions were observed in the 1X-dose group,and the 3X-and 5X-dose groups had an increase in ulcers and erosions of the tongue, lips and gums,Merial reports.

EQUIOXX, an oral paste, is approved for use up to 14 days for the control of pain and inflammation associated with equine osteoarthritis.It is a prescription product available through veterinarians. The recommended dose is 0.045 mg/lb (0.1 mg/kg) body weight.

For fastest response, call

(888) MERIAL1

www.equioxx.com.


Advertisement

Latest News

An update on copper concerns in pet foods

Dental hacks to make every case more manageable

Q&A with a keynote: Walter Brown, RVTg, VTS, ECC

News wrap-up: This week’s headlines, plus dvm360® launches its first CE podcast

View More Latest News
Advertisement